Tallman MS - Search Results

1

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Stein EM, et al. Among authors: tallman ms. Blood. 2021 Apr 1;137(13):1792-1803. doi: 10.1182/blood.2020007233. Blood. 2021. PMID: 33024987 Free PMC article. Clinical Trial.

2

A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia.

Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K. Tallman MS, et al. Blood. 1992 Nov 1;80(9):2203-9. Blood. 1992. PMID: 1358262 Free article.

3

Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.

Tallman MS, Kwaan HC. Tallman MS, et al. Blood. 1992 Feb 1;79(3):543-53. Blood. 1992. PMID: 1732003 Free article. Review. No abstract available.

4

Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.

Tallman MS, Hakimian D. Tallman MS, et al. Blood. 1995 Oct 1;86(7):2463-74. Blood. 1995. PMID: 7670093 Free article. Review. No abstract available.

5

Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.

Hakimian D, Tallman MS, Kiley C, Peterson L. Hakimian D, et al. Among authors: tallman ms. Blood. 1993 Sep 15;82(6):1798-802. Blood. 1993. PMID: 7691237 Free article.

6

Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid.

Tallman MS, Rowe JM. Tallman MS, et al. Blood Rev. 1994 Jun;8(2):70-8. doi: 10.1016/s0268-960x(05)80010-4. Blood Rev. 1994. PMID: 7950477 Review. No abstract available.

7

Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.

Kuzel TM, Hurria A, Samuelson E, Tallman MS, Roenigk HH Jr, Rademaker AW, Rosen ST. Kuzel TM, et al. Among authors: tallman ms. Blood. 1996 Feb 1;87(3):906-11. Blood. 1996. PMID: 8562961 Free article. Clinical Trial.

8

Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.

Wheaton S, Tallman MS, Hakimian D, Peterson L. Wheaton S, et al. Among authors: tallman ms. Blood. 1996 Feb 15;87(4):1556-60. Blood. 1996. PMID: 8608247 Free article.

9

Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience.

Tallman MS, Hakimian D, Rademaker AW, Zanzig C, Wollins E, Rose E, Peterson LC. Tallman MS, et al. Blood. 1996 Sep 15;88(6):1954-9. Blood. 1996. PMID: 8822913 Free article. Clinical Trial.

10

Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.

Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH. Gallagher RE, et al. Among authors: tallman ms. Blood. 1997 Aug 15;90(4):1656-63. Blood. 1997. PMID: 9269786 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

674 results

Search Page

Filters